SparingVision is a genomic medicines company, translating pioneering science into vision-saving treatments. Founded to advance over 20 years of world-leading ophthalmic research from its scientific founders at the Paris Vision Institute, SparingVision is leading a step shift in how ocular diseases are treated, moving beyond single gene correction therapies.
At the heart of this is a pipeline of gene independent treatments for rod-cone dystrophies. Lead products, SPVN06 and SPVN20, address mid and late stages of retinitis pigmentosa (RP)respectively. RP is the most common inherited retinal disease affecting two million people worldwide. These novel medicines could form the basis of a suite of new sight-saving treatments with potential applications across many other retinal diseases, regardless of genetic cause.
The Company is supported by a strong, internationally renowned team who aim to harness the potential of genomic medicine to deliver new treatments to all ocular disease patients as quickly as possible. SparingVision has raised €60 million to date and its investors include 4BIO Capital, Advent France Biotechnology, Bpifrance, Foundation Fighting Blindness (US), Fondation Voir & Entendre, UPMC Enterprises, Jeito Capital and Ysios Capital. For more information, please visit www.sparingvision.com.
At the heart of this is a pipeline of gene independent treatments for rod-cone dystrophies. Lead products, SPVN06 and SPVN20, address mid and late stages of retinitis pigmentosa (RP)respectively. RP is the most common inherited retinal disease affecting two million people worldwide. These novel medicines could form the basis of a suite of new sight-saving treatments with potential applications across many other retinal diseases, regardless of genetic cause.
The Company is supported by a strong, internationally renowned team who aim to harness the potential of genomic medicine to deliver new treatments to all ocular disease patients as quickly as possible. SparingVision has raised €60 million to date and its investors include 4BIO Capital, Advent France Biotechnology, Bpifrance, Foundation Fighting Blindness (US), Fondation Voir & Entendre, UPMC Enterprises, Jeito Capital and Ysios Capital. For more information, please visit www.sparingvision.com.
Location: France, Ile-de-France, Paris
Employees: 11-50
Total raised: $202.94M
Founded date: 2016
Investors 3
| Date | Name | Website |
| 13.05.2024 | Jeito Capi... | jeito.life |
| - | Ysios Capi... | ysioscapit... |
| - | Retinal De... | retinaldeg... |
Funding Rounds 3
| Date | Series | Amount | Investors |
| 18.09.2022 | Series B | $75.2M | Jeito Capi... |
| 14.09.2022 | Series A | $75M | UPMC Enter... |
| 27.10.2020 | - | $52.74M | - |
Mentions in press and media 11
| Date | Title | Description |
| 02.12.2022 | SparingVision’s lead asset SPVN06 clears IND application in the US for retinitis pigmentosa | SparingVision set to advance into the clinic with breakthrough gene-independent approach targeting retinitis pigmentosa (RP), one of the leading causes of blindness globally |
| 17.09.2022 | SparingVision Raises €75 Million Series B | LONDON– 4BIO Capital (“4BIO” or “the Group”), an international venture capital firm unlocking the treatments of the future by investing in advanced therapies, including genomic medicines and other emerging technologies, OR a leading investo... |
| 14.09.2022 | SparingVision Raises €75 Million Series B to Continue Building World-Leading Portfolio of Genomic Medicines for Ocular Diseases | SparingVision Raises €75 Million Series B to Continue Building World-Leading Portfolio of Genomic Medicines for Ocular Diseases Proceeds to fund first-in-human trials of breakthrough gene therapy products, SPVN06 and SPVN20, and advance CRI... |
| 14.09.2022 | SparingVision Raises €75M in Series B Funding | SparingVision, a French biotech company, raised €75m in Series B funding. The round was co-led by Jeito Capital and the University of Pittsburgh Medical Center Enterprise (UMPCE), with participation from Ysios Capital, 4Bio, Bpifrance and t... |
| 10.06.2022 | 42 start-ups through to Catapult 2022-23 semifinals | We are excited to today announce the 42 promising start-ups that will go through to the semifinals of EIT Health Catapult 2022-23. Each year, the competition showcases Europe’s most promising biotech, medtech and digital health start-ups to... |
| 13.10.2021 | SparingVision announces strategic collaboration with Intellia Therapeutics | London, 13 October 2020 – 4BIO Capital (“4BIO” or “the Group”), an international venture capital firm focused solely on the advanced therapies sector, announced today that its portfolio company SparingVision, a genomic medicine company deve... |
| 27.10.2020 | French startup SparingVision raises $52.6 million | French startup SparingVision raises $52.6 million 27 October, 2020, 15:00 Alexandra Minchuk --> --> --> -->--> --> --> --> --> --> --> --> --> SparingVision, a genomic medicine company focused on oc... |
| 21.10.2020 | SparingVision cierra una ronda de €44,5M liderada por 4BIO Capital y el UPMCE, acuden también Ysios, Jeito Capital y los existentes Bpifrance y Foundation Fighting | 21/10/2020 Nota de prensa YSIOS CAPITAL PARTICIPA EN LA RONDA DE FINANCIACIÓN DE €44,5 MILLONES DE SPARINGVISION. − SparingVision (París, Francia), es una compañía biotecnológica especializada en el desarrollo de terapias innovadoras par... |
| 21.10.2020 | 4BIO Capital leads SparingVision’s €44.5 million financing round | LONDON & BOSTON – 4BIO Capital (“4BIO” or “the Group”), an international venture capital firm focused solely on the advanced therapies sector, announces its investment in SparingVision, a genomic medicine company focused on ocular disea... |
| - | SparingVision | “We are a genomic medicines company leading a step shift in how ocular diseases are treated. We are going beyond single gene correction therapies to deliver new treatments as quickly as possible to patients affected by Inherited Retinal Dis... |
Show more